Roland D Chapurlat

List of Publications by Year
in descending order

102 papers	6,420 citations	57758 44 h-index	66911 78 g-index
112 all docs	112 docs citations	112 times ranked	5828 citing authors

#	Article	IF	Citations
1	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes and Endocrinology,the, 2017, 5, 513-523.	11.4	635
2	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. Journal of Bone and Mineral Research, 2016, 31, 940-948.	2.8	508
3	Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research, 2012, 27, 694-701.	2.8	290
4	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 34-43.	11.4	244
5	Bone remodelling in humans is load-driven but not lazy. Nature Communications, 2014, 5, 4855.	12.8	212
6	Long-Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of Bone. Journal of Bone and Mineral Research, 1997, 12, 1746-1752.	2.8	208
7	Fibrous dysplasia of bone and McCuneâ€“Albright syndrome. Best Practice and Research in Clinical Rheumatology, 2008, 22, 55-69.	3.3	186
8	2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine, 2012, 79, 304-313.	1.6	166
9	Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. Bone, 2010, 46, 1030-1037.	2.9	153
10	Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet Journal of Rare Diseases, 2019, 14, 139.	2.7	149
11	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes and Endocrinology,the, 2018, 6, 445-454.	11.4	148
12	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 15-24.	2.7	146
13	Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study. Journal of Bone and Mineral Research, 2007, 22, 1502-1509.	2.8	135
14	Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. Journal of Bone and Mineral Research, 2011, 26, 965-973.	2.8	126
15	Medical Therapy in Adults With Fibrous Dysplasia of Bone. Journal of Bone and Mineral Research, 2006, 21, P114-P119.	2.8	120
16	Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 571-580.	3.6	119
17	Bone Microarchitecture Assessed by HRâ€pQCT as Predictor of Fracture Risk in Postmenopausal Women: The OFELY Study. Journal of Bone and Mineral Research, 2017, 32, 1243-1251.	2.8	111
18	High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nature Reviews Rheumatology, 2014, 10, 304-313.	8.0	103

#	Article	IF	Citations
19	Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. Journal of Bone and Mineral Research, 2013, 28, 524-536.	2.8	98
20	Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. Journal of Bone and Mineral Research, 2019, 34, 1597-1608.	2.8	98
21	Fibrous dysplasia of bone. Best Practice and Research in Clinical Rheumatology, 2000, 14, 385-398.	3.3	96
22	Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. Journal of Bone and Mineral Research, 2012, 27, 825-834.	2.8	96
23	Serum Estradiol and Sex Hormone-Binding Globulin and the Risk of Hip Fracture in Elderly Women: The EPIDOS Study. Journal of Bone and Mineral Research, 2000, 15, 1835-1841.	2.8	94
24	Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: The STRAMBO study. Journal of Bone and Mineral Research, 2011, 26, 1358-1367.	2.8	94
25	The FRAX tool in French women: How well does it describe the real incidence of fracture in the OFELY cohort. Journal of Bone and Mineral Research, 2010, 25, 2101-2107.	2.8	91
26	Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatology, 2016, 55, 1714-1725.	1.9	81
27	Challenges in longitudinal measurements with HR-pQCT: Evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility. Bone, 2014, 63, 147-157.	2.9	80
28	The Ratio 1660/1690 cmâˆ’1 Measured by Infrared Microspectroscopy Is Not Specific of Enzymatic Collagen Cross-Links in Bone Tissue. PLoS ONE, 2011, 6, e28736.	2.5	74
29	Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine, 2017, 84, 427-432.	1.6	70
30	Microarchitecture and Peripheral BMD are Impaired in Postmenopausal White Women With Fracture Independently of Total Hip T-Score: An International Multicenter Study. Journal of Bone and Mineral Research, 2016, 31, 1158-1166.	2.8	69
31	Association between bone turnover rate and bone microarchitecture in men: The STRAMBO study. Journal of Bone and Mineral Research, 2010, 25, 2313-2323.	2.8	67
32	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	2.5	63
33	Lower fracture risk in older men with higher sclerostin concentration: A prospective analysis from the MINOS study. Journal of Bone and Mineral Research, 2013, 28, 855-864.	2.8	59
34	Predicting fractures in an international cohort using risk factor algorithms without BMD. Journal of Bone and Mineral Research, 2011, 26, 2770-2777.	2.8	58
35	Higher Serum Osteocalcin Is Associated With Lower Abdominal Aortic Calcification Progression and Longer 10-Year Survival in Elderly Men of the MINOS Cohort. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1084-1092.	3.6	58
36	Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength. Journal of Bone and Mineral Research, 2014, 29, 1786-1794.	2.8	58

#	Article	IF	Citations
37	Fibrous dysplasia and McCuneâ€“Albright syndrome: Imaging for positive and differential diagnoses, prognosis, and follow-up guidelines. European Journal of Radiology, 2014, 83, 1828-1842.	2.6	57
38	Age-related changes in bone strength from HR-pQCT derived microarchitectural parameters with an emphasis on the role of cortical porosity. Bone, 2016, 83, 233-240.	2.9	57
39	Mechanisms of the Anabolic Effects of Teriparatide on Bone: Insight From the Treatment of a Patient With Pycnodysostosis. Journal of Bone and Mineral Research, 2008, 23, 1076-1083.	2.8	56
40	Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4727-4735.	3.6	50
41	Impaired bone microarchitecture at the distal radius in older men with low muscle mass and grip strength: The STRAMBO study. Journal of Bone and Mineral Research, 2013, 28, 169-178.	2.8	50
42	Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 103-109.	2.7	48
43	Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. European Journal of Endocrinology, 2011, 165, 647-655.	3.7	47
44	Trabecular Bone Score: Where are we now?. Joint Bone Spine, 2015, 82, 320-325.	1.6	45
45	Serum Sortilin Associates With Aortic Calcification and Cardiovascular Risk in Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1005-1011.	2.4	44
46	Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. European Journal of Endocrinology, 2012, 166, 735-741.	3.7	37
47	Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. Joint Bone Spine, 2014, 81, 549-550.	1.6	37
48	Risedronate Slows or Partly Reverses Cortical and Trabecular Microarchitectural Deterioration in Postmenopausal Women. Journal of Bone and Mineral Research, 2014, 29, 380-388.	2.8	37
49	Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study. Journal of Bone and Mineral Research, 2016, 31, 2167-2172.	2.8	37
50	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. Journal of Bone and Mineral Research, 2021, 36, 2139-2152.	2.8	35
51	Deterioration of Cortical and Trabecular Microstructure Identifies Women With Osteopenia or Normal Bone Mineral Density at Imminent and Longâ€Term Risk for Fragility Fracture: A Prospective Study. Journal of Bone and Mineral Research, 2020, 35, 833-844.	2.8	33
52	Association Between Sex Steroid Levels and Bone Microarchitecture in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1400-1410.	3.6	32
53	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	2.8	29
54	Least-detectable and age-related local in vivo bone remodelling assessed by time-lapse HR-pQCT. PLoS ONE, 2018, 13, e0191369.	2.5	28

#	Article	IF	Citations
55	Lower serum osteocalcin is associated with more severe metabolic syndrome in elderly men from the MINOS cohort. European Journal of Endocrinology, 2014, 171, 275-283.	3.7	27
56	Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine, 2014, 81, 175-177.	1.6	26
57	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2018, 48, 1-8.	3.4	25
58	Bone Microarchitecture Phenotypes Identified in Older Adults Are Associated With Different Levels of Osteoporotic Fracture Risk. Journal of Bone and Mineral Research, 2020, 37, 428-439.	2.8	24
59	Lack of Association Between Select Circulating miRNAs and Bone Mass, Turnover, and Fractures: Data From the OFELY Cohort. Journal of Bone and Mineral Research, 2019, 34, 1074-1085.	2.8	21
60	Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone, 2021, 143, 115784.	2.9	21
61	Emerging drugs for osteoporosis. Expert Opinion on Emerging Drugs, 2014, 19, 385-395.	2.4	19
62	High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. Journal of Rheumatology, 2016, 43, 657-665.	2.0	16
63	Effects and management of denosumab discontinuation. Joint Bone Spine, 2018, 85, 515-517.	1.6	16
64	Relationship Between Sex Steroids and Deterioration of Bone Microarchitecture in Older Men: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2019, 34, 1562-1573.	2.8	16
65	Modeling-Based Bone Formation After 2â€‰Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. Journal of Bone and Mineral Research, 2020, 37, 36-40.	2.8	16
66	Contribution of high resolution peripheral quantitative CT to the management of bone and joint diseases. Joint Bone Spine, 2018, 85, 301-306.	1.6	15
67	Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture. PLoS ONE, 2019, 14, e0216947.	2.5	15
68	Contribution and limitations of the FRAXÂ® tool. Joint Bone Spine, 2013, 80, 355-357.	1.6	14
69	Feasibility of rigid 3D image registration of high-resolution peripheral quantitative computed tomography images of healing distal radius fractures. PLoS ONE, 2017, 12, e0179413.	2.5	14
70	Treatment of postmenopausal osteoporosis with odanacatib. Expert Opinion on Pharmacotherapy, 2014, 15, 559-564.	1.8	12
71	Erosion or Vascular Channel?. Arthritis and Rheumatology, 2015, 67, 2956-2956.	5.6	12
72	Assessment of the clinical relevance of pharmacists' interventions performed during medication review in a rheumatology ward. European Journal of Internal Medicine, 2019, 59, 91-96.	2.2	10

#	Article	IF	Citations
73	A Signature of Circulating <scp>miRNAs</scp> Associated With Fibrous Dysplasia of Bone: the <scp>mirDys</scp> Study. Journal of Bone and Mineral Research, 2020, 35, 1881-1892.	2.8	10
74	Imminent fracture risk. Joint Bone Spine, 2021, 88, 105105.	1.6	10
75	Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial. Bone, 2022, 157, 116343.	2.9	10
76	Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFÎ± blocker. Joint Bone Spine, 2014, 81, 455-456.	1.6	9
77	The QUALYOR (QUalitÃ© Osseuse LYon OrlÃ©ans) study: a new cohort for non invasive evaluation of bone quality in postmenopausal osteoporosis. Rationale and study design. Archives of Osteoporosis, 2018, 13, 2.	2.4	9
78	Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporosis International, 2021, 32, 173-184.	3.1	9
79	Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. Journal of Bone and Mineral Research, 2020, 36, 1031-1041.	2.8	9
80	The bone strain index predicts fragility fractures. The OFELY study. Bone, 2022, 157, 116348.	2.9	9
81	Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?. Joint Bone Spine, 2016, 83, 254-256.	1.6	8
82	In vivo evaluation of bone microstructure in humans: Clinically useful?. BoneKEy Reports, 2016, 5, 813.	2.7	8
83	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2017, 32, 2288-2296.	2.8	7
84	Review of ibandronate in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 2003, 4, 391-396.	1.8	6
85	Older men with severe disc degeneration have more incident vertebral fracturesâ€"the prospective MINOS cohort study. Rheumatology, 2017, 56, 37-45.	1.9	6
86	Reliability and Change in Erosion Measurements by High-resolution Peripheral Quantitative Computed Tomography in a Longitudinal Dataset of Rheumatoid Arthritis Patients. Journal of Rheumatology, 2021, 48, 348-351.	2.0	6
87	Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. Journal of Bone and Mineral Research, 2020, 37, 1136-1146.	2.8	6
88	Long term prognosis of Scheuermann's disease: The association with fragility fracture - The MINOS cohort. Bone, 2018, 117, 116-122.	2.9	5
89	High Cardiovascular Risk in Older Men with Poor Bone Microarchitectureâ€"The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2020, 36, 879-891.	2.8	5
90	A Novel HR-pQCT Image Registration Approach Reveals Sex-Specific Changes in Cortical Bone Retraction With Aging. Journal of Bone and Mineral Research, 2020, 36, 1351-1363.	2.8	5

#	Article	IF	Citations
91	Bone Microarchitecture Decline and Risk of Fall and Fracture in Men With Poor Physical Performanceâ€"The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5180-e5194.	3.6	5
92	Elevated lipoprotein(a) as a predictor for coronary events in older men. Journal of Lipid Research, 2022, 63, 100242.	4.2	4
93	Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Therapeutics and Clinical Risk Management, 2009, 5, 169.	2.0	3
94	Estimation of Longâ€Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAXâ€•and Virtual Twinâ€Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. JBMR Plus, 2020, 4, e10348.	2.7	3
95	Single annual injectable treatment for postmenopausal osteoporosis. Expert Opinion on Drug Delivery, 2008, 5, 583-591.	5.0	2
96	Regional Differences in Incident Prefrailty and Frailty. Journal of Women's Health, 2017, 26, 992-998.	3.3	2
97	Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database. Joint Bone Spine, 2022, 89, 105340.	1.6	2
98	OstÃ©oporose et maladies cardiovasculaires ischÃ©miques. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 117-122.	0.0	1
99	Reliability of the assessment of disc degeneration on the lateral DXA scans. Joint Bone Spine, 2021, 88, 105123.	1.6	1
100	UtilitÃ© du scanner pÃ©riphÃ©rique Ã haute rÃ©solution dans la prise en charge des maladies ostÃ©oarticulaires. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 138-145.	0.0	0
101	Of the Futility of Repeating BMD Measurement in Treated Osteoporotic Women. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4784-e4785.	3.6	0
102	Implementation and effectiveness of pharmacist-led interviews at patient hospital admission in a rheumatology department. European Journal of Hospital Pharmacy, 2023, 30, 273-278.	1.1	0